Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Fall 2021 RFP: Outcome Measures, 2021
    Development of Novel Antibodies that Facilitate the Accurate Measurement of All Forms of Alpha-synuclein Present in Biological Fluids

    Study Rationale: The ability to accurately detect and quantify alpha-synuclein and its pathology-relevant variants represents a major challenge in Parkinson’s disease (PD). Different studies report...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Impact of TRPML1 Stimulation on Clinical Biomarkers and Synuclein Pathology

    Study Rationale: The protein TRPML1 regulates the clearance of cellular debris, including aggregated alpha-synuclein and toxic lipids—a process that is disrupted in Parkinson’s disease (PD). We have...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease

    Study Rationale: The aggregation of alpha-synuclein and tau converts these proteins from a biologically functional state into toxic, fibrous deposits in the brains of people with Parkinson’s disease...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Development of Novel Brain-penetrant Inflammasome Inhibitors as Potential Therapeutics for Parkinson’s Disease

    Study Rationale: The immune system displays an aberrant pattern of activity in the central nervous system of people with Parkinson’s disease (PD); this pattern includes activation of a danger-sensing...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Development of a Small-molecule Inhibitor Targeting Intracellular Alpha-synuclein Pathology

    Study Rationale: Parkinson’s disease (PD) and other devastating neurodegenerative diseases, including Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA), are characterized by the...

  • Fall 2021 RFP: Outcome Measures, 2021
    Use of Image-enhancement Techniques to Assess Anatomical Changes in Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) has several subtypes. Identification of these subtypes in individuals with PD is important for understanding disease progression, developing new therapies...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.